Inhalation Sciences ships second fully commercialized DissolvIt module in one week
Following the historic shipment of its first commercialized DissolvIt[®] in vitro module, Inhalation Sciences has shipped a second module, to a returning pharmaceutical customer, within the same week. The customer placed the original purchase order for DissolvIt, worth 75,000 Euro (835,000 SEK), in December 2018. “We’ve long known DissolvIt was in demand” says CEO Manoush Masarrat, “this really proves it.”The latest, second commercialized module has been shipped to a long-term ISAB pharma company in Southern Europe. After ten years in development DissolvIt has been tested in many contract